 |
|
Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology
Silvia Sookoian, Carlos J. Pirola
Clin Mol Hepatol. 2020;26(4):461-475. Published online 2020 Sep 10 DOI: https://doi.org/10.3350/cmh.2020.0136
|
|
Citations to this article as recorded by
 The sulfur microbial diet and risk of nonalcoholic fatty liver disease: a prospective gene–diet study from the UK Biobank
Zhening Liu, Hangkai Huang, Jiaqi Ruan, Zejun Wang, Chengfu Xu
The American Journal of Clinical Nutrition.2024; 119(2): 417. CrossRef Exploration of the Key Genes Involved in Non-alcoholic Fatty Liver Disease and Possible MicroRNA Therapeutic Targets
Ali Mahmoudi, Amin Jalili, Alexandra E. Butler, Seyed H. Aghaee-Bakhtiari, Tannaz Jamialahmadi, Amirhossein Sahebkar
Journal of Clinical and Experimental Hepatology.2024; 14(4): 101365. CrossRef siRNA-mediated gene silencing for non-alcoholic fatty liver disease: A comprehensive review of molecular targets
Ali Mahmoudi, Mehdi Rostami, Mohammad Mahdi Hajihasani, Vasily N. Sukhorukov, Prashant Kesharwani, Amirhossein Sahebkar
European Polymer Journal.2024; 208: 112866. CrossRef PARVB and HSD17B13 variants are associated with nonalcoholic fatty liver disease in children
Kyung Jae Lee, Jin Soo Moon, Jin Gyu Lim, Homin Huh, Jeong Eun Ahn, Lia Kim, Nan Young Kim, Jae Sung Ko
Journal of Gastroenterology and Hepatology.2024;[Epub] CrossRef Analysis of the therapeutic potential of miR-124 and miR-16 in non-alcoholic fatty liver disease
Ali Mahmoudi, Amin Jalili, Seyed Hamid Aghaee-Bakhtiari, Reza Kazemi Oskuee, Alexandra E. Butler, Manfredi Rizzo, Amirhossein Sahebkar
Journal of Diabetes and its Complications.2024; 38(4): 108722. CrossRef Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
Seyedeh Kosar Mahmoudi, Shadi Tarzemani, Taha Aghajanzadeh, Mohammadreza Kasravi, Behzad Hatami, Mohammad Reza Zali, Kaveh Baghaei
European Journal of Medical Research.2024;[Epub] CrossRef Shining a spotlight on sarcopenia and myosteatosis in liver disease and liver transplantation
Sophie Reichelt, Uta Merle, Miriam Klauss, Christoph Kahlert, Georg Lurje, Arianeb Mehrabi, Zoltan Czigany
Liver International.2024;[Epub] CrossRef Non-alcoholic fatty liver disease: the pathologist’s perspective
Wei-Qiang Leow, Anthony Wing-Hung Chan, Paulo Giovanni L. Mendoza, Regina Lo, Kihan Yap, Haeryoung Kim
Clinical and Molecular Hepatology.2023; 29(Suppl): S302. CrossRef Non-alcoholic fatty liver disease: Definition and subtypes
Seul Ki Han, Soon Koo Baik, Moon Young Kim
Clinical and Molecular Hepatology.2023; 29(Suppl): S5. CrossRef Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response
Silvia Sookoian, Carlos J. Pirola
Clinical and Molecular Hepatology.2023; 29(Suppl): S184. CrossRef Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease
Georg Semmler, Christian Datz, Michael Trauner
Clinical and Molecular Hepatology.2023; 29(Suppl): S244. CrossRef Advances in our understanding of the molecular heterogeneity of fatty liver disease: toward informed treatment decision making
Carlos J Pirola, Silvia Sookoian
Expert Review of Gastroenterology & Hepatology.2023; 17(4): 317. CrossRef Identification of disease-related genes and construction of a gene co-expression database in non-alcoholic fatty liver disease
Hua Ye, Mengxia Sun, Mingli Su, Dahua Chen, Huiwei Liu, Yanyan Ma, Wenjing Luo, Hong Li, Feng Xu
Frontiers in Genetics.2023;[Epub] CrossRef Examining genetic associations with hepatic steatosis in Mexican-origin adults
Mario Jesus Trejo, Kristin E. Morrill, Yann C. Klimentidis, David O. Garcia
Annals of Hepatology.2023; 28(5): 101120. CrossRef Exploring the Role of Enhancer-Mediated Transcriptional Regulation in Precision Biology
Xueyan Wang, Danli Liu, Jing Luo, Dashuai Kong, Yubo Zhang
International Journal of Molecular Sciences.2023; 24(13): 10843. CrossRef Associations of MAFLD and MAFLD subtypes with the risk of the incident myocardial infarction and stroke
Shen Chen, Hongliang Xue, Rong Huang, Ke Chen, Haoyang Zhang, Xu Chen
Diabetes & Metabolism.2023; 49(5): 101468. CrossRef Serum metabolomic profiling unveils distinct sex-related metabolic patterns in NAFLD
Charalambos Fotakis, Ioanna-Panagiota Kalafati, Athina I. Amanatidou, Vasiliki Andreou, Manolis Matzapetakis, Maria Kafyra, Iraklis Varlamis, Maria Zervou, George V. Dedoussis
Frontiers in Endocrinology.2023;[Epub] CrossRef Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease
Chander K. Negi, Pavel Babica, Lola Bajard, Julie Bienertova-Vasku, Giovanni Tarantino
Metabolism.2022; 126: 154925. CrossRef Effects of PNPLA3, TM6SF2 and SAMM50 on the development and severity of non‐alcoholic fatty liver disease in children
Kyung Jae Lee, Jin Soo Moon, Nan Young Kim, Jae Sung Ko
Pediatric Obesity.2022;[Epub] CrossRef Metabolic dysfunction-associated fatty liver disease: advances in genetic and epigenetic implications
Carlos J. Pirola, Silvia Sookoian
Current Opinion in Lipidology.2022; 33(2): 95. CrossRef Investigation of the Effect of Curcumin on Protein Targets in NAFLD Using Bioinformatic Analysis
Ali Mahmoudi, Alexandra E. Butler, Muhammed Majeed, Maciej Banach, Amirhossein Sahebkar
Nutrients.2022; 14(7): 1331. CrossRef TissueSpace: a web tool for rank-based transcriptome representation and its applications in molecular medicine
Yiruo He, Wei Liu
Genes & Genomics.2022; 44(7): 793. CrossRef Intrahepatic inflammatory IgA+PD-L1high monocytes in hepatocellular carcinoma development and immunotherapy
Pil Soo Sung, Dong Jun Park, Pu Reun Roh, Kyoung Do Mun, Sung Woo Cho, Gil Won Lee, Eun Sun Jung, Sung Hak Lee, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Jonghwan Choi, Jaegyoon Ahn, Seung Kew Yoon
Journal for ImmunoTherapy of Cancer.2022; 10(5): e003618. CrossRef Precision medicine in nonalcoholic fatty liver disease
Amedeo Lonardo
Journal of Gastroenterology and Hepatology.2022; 37(7): 1175. CrossRef Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update
Nicholas W. S. Chew, Cheng Han Ng, Emily Truong, Mazen Noureddin, Kris V. Kowdley
Seminars in Liver Disease.2022; 42(03): 379. CrossRef Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD
Beom Kyung Kim, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Tuo Lin, Xin M. Tu, Jaclyn Bergstrom, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi N
Journal of Hepatology.2022; 77(6): 1482. CrossRef Personalized medicine in nonalcoholic fatty liver disease
Carlos J. Pirola, Silvia Sookoian
Clinical and Molecular Hepatology.2022; 28(4): 935. CrossRef Pleiotropy within gene variants associated with nonalcoholic fatty liver disease and traits of the hematopoietic system
Carlos Jose Pirola, Adrian Salatino, Silvia Sookoian
World Journal of Gastroenterology.2021; 27(4): 305. CrossRef The lipidome in nonalcoholic fatty liver disease: actionable targets
Carlos J. Pirola, Silvia Sookoian
Journal of Lipid Research.2021; 62: 100073. CrossRef Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity
Marco Arrese, Juan P. Arab, Francisco Barrera, Benedikt Kaufmann, Luca Valenti, Ariel E. Feldstein
Seminars in Liver Disease.2021; 41(04): 421. CrossRef From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Seong Hee Kang, Yuri Cho, Soung Won Jeong, Seung Up Kim, Jin-Woo Lee
Clinical and Molecular Hepatology.2021; 27(2): 257. CrossRef Body weight variability and the risk of cardiovascular outcomes in patients with nonalcoholic fatty liver disease
Mi Na Kim, Kyungdo Han, Juhwan Yoo, Yeonjung Ha, Young Eun Chon, Ju Ho Lee, Tracey G. Simon, Andrew T. Chan, Seong Gyu Hwang
Scientific Reports.2021;[Epub] CrossRef Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management
Amedeo Lonardo, Juan Pablo Arab, Marco Arrese
Advances in Therapy.2021; 38(5): 2130. CrossRef Genetic risk scores and personalization of care in fatty liver disease
Cristiana Bianco, Federica Tavaglione, Stefano Romeo, Luca Valenti
Current Opinion in Pharmacology.2021; 61: 6. CrossRef NAFLD and Cardiometabolic Risk Factors: The Liver Fibrosis Trajectory Through the Lens of Biological Interactions
Carlos J. Pirola, Silvia Sookoian
Hepatology.2021; 73(2): 479. CrossRef Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis
Ali Mahmoudi, Alexandra E. Butler, Tannaz Jamialahmadi, Amirhossein Sahebkar, Bing Niu
BioMed Research International.2021; 2021: 1. CrossRef Editorial on Prevalence, Diagnosis and Treatment with 3 Different Statins of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?
Emir Muzurović, Brigita Smolović, Snežana Vujošević, Milan Petakov
Current Vascular Pharmacology.2021; 19(5): 582. CrossRef
|